                         SEQUENCE LISTING

<110>  Agency for Science, Technology and Research
 
<120>  ANTI-CEACAM6 ANTIBODIES AND METHODS OF USE

<130>  9869SG4671

<160>  8     

<170>  PatentIn version 3.5

<210>  1
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Isolated antibody fragment

<400>  1

Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Met Ser Cys 
1               5                   10                  15      


Lys Ala Ser Gly Asn Thr Phe Thr Ser Tyr Val Met His Trp Val Lys 
            20                  25                  30          


Gln Lys Pro Gly Gln Gly Leu Glu Trp Ile Gly Tyr Ile Asn Pro Tyr 
        35                  40                  45              


Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu 
    50                  55                  60                  


Thr Ser Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu 
65                  70                  75                  80  


Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Ser Thr Ala Arg 
                85                  90                  95      


Ala Thr Pro Tyr Phe Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser 
            100                 105                 110         


Val Thr Val Ser Ser 
        115         


<210>  2
<211>  115
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Isolated antibody fragment

<400>  2

Asp Ile Leu Met Thr Gln Ser Pro Ser Ser Leu Ala Val Thr Ala Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Arg Cys Lys Ser Ser Gln Ser Leu Leu Trp Ser 
            20                  25                  30          


Val Asn Gln Asn Ser Tyr Leu Ser Trp Tyr Gln Leu Lys Gln Gly Gln 
        35                  40                  45              


Pro Pro Lys Leu Leu Leu Tyr Gly Ala Ser Ile Arg Glu Ser Trp Val 
    50                  55                  60                  


Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65                  70                  75                  80  


Ile Ser Asn Val His Val Glu Asp Leu Ala Val Tyr Tyr Cys Gln His 
                85                  90                  95      


Asn His Gly Ser Phe Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu 
            100                 105                 110         


Glu Ile Lys 
        115 


<210>  3
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Isolated antibody fragment

<400>  3

Gly Asn Thr Phe Thr Ser Tyr Val Met His 
1               5                   10  


<210>  4
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Isolated antibody fragment

<400>  4

Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys 
1               5                   10                  15      


Gly 
    


<210>  5
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Isolated antibody fragment

<400>  5

Ser Thr Ala Arg Ala Thr Pro Tyr Phe Tyr Ala Met Asp Tyr 
1               5                   10                  


<210>  6
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Isolated antibody fragment

<400>  6

Ser Ser Gln Ser Leu Leu Trp Ser Val Asn Gln Asn Ser Tyr Leu Ser 
1               5                   10                  15      


<210>  7
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Isolated antibody fragment

<400>  7

Gly Ala Ser Ile Arg Glu Ser 
1               5           


<210>  8
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Isolated antibody fragment

<400>  8

Gln His Asn His Gly Ser Phe Leu Pro Tyr Thr 
1               5                   10      


